Bioheng
Latest round
- Series B
Last raised
- Mar 2021
Total raised
- $94M
Investors
- 5
About Bioheng
Bioheng Therapeutics is dedicated to the development of allogeneic 'off-the-shelf' CAR-T therapies. The company was founded by Lu Han and Xiaohong He.Bioheng Therapeutics specializes in the development of allogeneic 'off-the-shelf' universal CAR-T therapies, leveraging its proprietary UCAR-T technology platform known as ANSWER®. Their primary products, including the CD7-targeted UCAR-T therapy CTD40X, address unmet needs in treating hematological malignancies, particularly T-cell acute lymphoblastic leukemia (T-ALL). Bioheng received Investigational New Drug (IND) approval for CTA101 in March 2022, and its therapeutic products are in advanced clinical trials aimed at enhancing treatment efficacy.Bioheng Therapeutics generates revenue through partnerships and collaborations with healthcare institutions and pharmaceutical partners focused on innovative therapeutic solutions for cancer and autoimmune diseases. The company intends to expand its market presence in the United States and potentially other international markets by 2023, aiming to enhance access to its innovative CAR-T therapies.
Who invested in Bioheng
5 investors across 2 rounds
See all investors in Bioheng
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Bioheng
Who invested in Bioheng?
Bioheng has 5 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Bioheng raised?
Bioheng has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Bioheng last raise money?
Bioheng's most recent round on record is a Series B, in Mar 2021.
What does Bioheng do?
Bioheng Therapeutics is dedicated to the development of allogeneic 'off-the-shelf' CAR-T therapies.
Where is Bioheng headquartered?
Bioheng is headquartered in Nanjing, China.
Which VCs invest in companies like Bioheng?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Bioheng's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Bioheng? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.